---
schema_version: "secwatch.filing_event.v1"
accession: "0001757073-25-000005"
form_type: "8-K"
ticker: "NVST"
cik: "0001757073"
company_name: "Envista Holdings Corp"
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:47:39.651352+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Envista Q4 net income $1M, core sales +2%; FY2025 adj EPS guide $0.95-$1.05

## Summary
- Q4 net income $1M vs loss of $217M a year ago; adjusted diluted EPS $0.24 vs $0.29.
- Full-year 2024 net loss $1.12B (incl. impairment), adjusted net income $127M vs $269M in 2023.
- Free cash flow $124M in Q4, up 24% YoY; operating cash flow $132M, up 30%.
- Implants improved with growth in Nobel Biocare, Implant Direct, Alpha-Bio; Spark aligners gained share and gross margin.
- FY2025 guidance: core sales growth 1-3%, adjusted EBITDA margin ~14%, adjusted EPS $0.95-$1.05.

## SEC filing metadata
- accession: 0001757073-25-000005
- form_type: 8-K
- ticker: NVST
- cik: 0001757073
- company_name: Envista Holdings Corp
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757073/000175707325000005/0001757073-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757073/000175707325000005/nvst-20250205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001757073-25-000005
- JSON: https://secwatch.observer/filing/0001757073-25-000005.json
- Plain text: https://secwatch.observer/filing/0001757073-25-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.